摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 3-(2-chloropyridin-3-yl)-3-oxopropionate | 220731-02-2

中文名称
——
中文别名
——
英文名称
ethyl 3-(2-chloropyridin-3-yl)-3-oxopropionate
英文别名
ethyl 2-(2-chloronicotinoyl)acetate;ethyl (2-chloronicotinoyl)acetate;Ethyl 3-(2-chloropyridin-3-yl)-3-oxopropanoate
ethyl 3-(2-chloropyridin-3-yl)-3-oxopropionate化学式
CAS
220731-02-2
化学式
C10H10ClNO3
mdl
——
分子量
227.647
InChiKey
MOOVARASKMIIJY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    309.0±27.0 °C(Predicted)
  • 密度:
    1.270±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    15
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    56.3
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl 3-(2-chloropyridin-3-yl)-3-oxopropionate乙酸酐 、 sodium hydride 、 三乙胺 、 sodium hydroxide 、 氯甲酸异丁酯 作用下, 以 四氢呋喃甲醇乙酸酐 、 mineral oil 为溶剂, 反应 23.83h, 生成 N-Isopropyl-1-(3-bromophenyl)-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide
    参考文献:
    名称:
    Alternative Forms of the Phosphodiesterase-4 Inhibitor N-Cyclopropyl-1--4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide
    摘要:
    本发明涉及选择性磷酸二酯酶4抑制剂的替代形式,其结构式如下所示:
    公开号:
    US20110245290A1
  • 作为产物:
    描述:
    盐酸 作用下, 以 为溶剂, 生成 ethyl 3-(2-chloropyridin-3-yl)-3-oxopropionate
    参考文献:
    名称:
    Optimization and structure–activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: Identification of MK-0873, a potent and effective PDE4 inhibitor
    摘要:
    A SAR study of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides is described. Optimization of the series was based on in vitro potency against PDE4, inhibition of the LPS-induced production of TNF-alpha in human whole blood and minimizing affinity for the hERG potassium channel. From these studies, compounds 18 and 20 (MK-0873) were identified as optimized PDE4 inhibitors with good overall in vitro and in vivo profiles and selected as development candidates. (c) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.09.009
点击查看最新优质反应信息

文献信息

  • 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
    申请人:——
    公开号:US20030096829A1
    公开(公告)日:2003-05-22
    Compounds represented by Formula (I): 1 or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.
    由化学式(I)表示的化合物: 1 或其药用可接受的盐,是磷酸二酯酶4抑制剂,用于治疗哮喘和炎症。
  • Alkyne-aryl phosphodiesterase-4 inhibitors
    申请人:——
    公开号:US20030114478A1
    公开(公告)日:2003-06-19
    Compounds represented by Formula (I): 1 or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.
    由公式(I)表示的化合物: 1 或其药用可接受的盐,是磷酸二酯酶4抑制剂,用于治疗哮喘和炎症。
  • Method of preparing inhibitors of phosphodiesterase-4
    申请人:——
    公开号:US20040102472A1
    公开(公告)日:2004-05-27
    In one aspect, the present invention is directed to a one pot method of preparing intermediates of Formula V, which are useful in making inhibitors of phosphodiesterase-4: 1 The present invention is also directed to a method of preparing phosphodiesterase inhibitors comprising the Formula 2
    在一个方面,本发明涉及一种制备Formula V中间体的一锅法,该中间体在制备磷酸二酯酶-4抑制剂时非常有用: 另外,本发明还涉及一种制备磷酸二酯酶抑制剂的方法,包括Formula 2。
  • 1-cycloalkyl-1,8-naphthyridin-4-one derivative as type IV phosphodiesterase inhibitor
    申请人:Suntory Limited
    公开号:US06331548B1
    公开(公告)日:2001-12-18
    A 1-cycloalkyl-1,8-naphthylidin-4-one derivative having the formula (I): wherein R1 indicates a substituted or unsubstituted cycloalkyl group or a substituted or unsubstituted heterocycloalkyl group, R2, R3, and R4 independently indicate a hydrogen atom, a substituted or unsubstituted lower alkyl group, or a halogen atom, X indicates a group NR5R6 or a group OR7, wherein R5 and R6 independently indicate a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, and R7 indicates a hydrogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group or a pharmaceutically acceptable salt or solvate thereof and a type IV phosphodiesterase inhibitor containing the same as an effective component.
    一种具有以下式(I)的1-环烷基-1,8-萘亚啉-4-酮衍生物:其中R1表示取代或未取代的环烷基或取代或未取代的杂环烷基,R2、R3和R4独立地表示氢原子、取代或未取代的较低烷基基团或卤素原子,X表示基团NR5R6或基团OR7,其中R5和R6独立地表示氢原子、取代或未取代的较低烷基基团、取代或未取代的环烷基基团、取代或未取代的芳基团或取代或未取代的杂芳基团,R7表示氢原子、取代或未取代的较低烷基基团或取代或未取代的环烷基基团或其药学上可接受的盐或溶剂和含有其作为有效成分的Ⅳ型磷酸二酯酶抑制剂。
  • [EN] 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS<br/>[FR] 4-OXO-1-(PHENYL-1,4-DIHYDRO-1,8-NAPTHYRIDINE-3-CARBOXAMIDE, A SUBSTITUTION EN 3, UTILES COMME INHIBITEURS DE PHOSPHODIESTERASE-4
    申请人:MERCK FROSST CANADA INC
    公开号:WO2004048374A1
    公开(公告)日:2004-06-10
    Compounds represented by Formula (I):or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition.
    式(I)表示的化合物:或其药学上可接受的盐,是磷酸二酯酶4抑制剂,可用于哮喘和炎症的治疗,并可用于认知能力的增强。
查看更多